---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-107609"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T14:05:32.146827+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Perspective Therapeutics Q2 net loss $21.5M, EPS -$0.29; cash $192M; VMT-α-NET Cohort 3 opened

## Summary
- Net loss of $21.5M ($0.29 per share) vs $11.7M ($0.18) in Q2 2024; operating expenses rose 65%.
- Cash, cash equivalents & short-term investments $192M as of June 30, sufficient into late 2026.
- R&D expenses $16.6M (+79% YoY) driven by clinical site activities and drug product costs.
- FDA alignment obtained to open Cohort 3 (6.0 mCi) for [212Pb]VMT-α-NET; two patients dosed as of July 31.
- VMT01 melanoma program: combination with nivolumab cohort opened; five monotherapy patients treated.

## SEC filing metadata
- accession: 0000950170-25-107609
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000095017025107609/0000950170-25-107609-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000095017025107609/catx-20250813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-107609
- JSON: https://secwatch.observer/filing/0000950170-25-107609.json
- Plain text: https://secwatch.observer/filing/0000950170-25-107609.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.